<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24283303</PMID>
<DateCompleted>
<Year>2016</Year>
<Month>04</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1742-1241</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>68</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2014</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>International journal of clinical practice</Title>
<ISOAbbreviation>Int. J. Clin. Pract.</ISOAbbreviation>
</Journal>
<ArticleTitle>GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.</ArticleTitle>
<Pagination>
<MedlinePgn>609-17</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/ijcp.12352</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) is a global, prospective, non-interventional study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in real-life practice, including Child-Pugh B patients who were excluded from clinical trials.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Patients with unresectable HCC, for whom the decision to treat with sorafenib, based on the approved label and prescribing guidelines, had been taken by their physician, were eligible for inclusion. Demographic data and disease/medical history were recorded at entry. Sorafenib dosing and adverse events (AEs) were collected at follow-up visits. The second interim analysis was undertaken when ~1500 treated patients were followed up for ≥ 4 months.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 1571 patients evaluable for safety, 61% had Child-Pugh A status and 23% Child-Pugh B. The majority of patients (74%) received the approved 800 mg initial sorafenib dose, regardless of Child-Pugh status; however, median duration of therapy was shorter in Child-Pugh B patients. The majority of drug-related AEs were grade 1 or 2, and the most commonly reported were consistent with previous reports. The incidence and nature of drug-related AEs were broadly similar across Child-Pugh, Barcelona Clinic Liver Cancer (BCLC) and initial dosing subgroups, and consistent with the overall population.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Consistent with the first interim analysis, overall safety profile and dosing strategy are similar across Child-Pugh subgroups. Safety findings also appear comparable irrespective of initial sorafenib dose or BCLC stage. Final analyses in &gt; 3000 patients are ongoing.</AbstractText>
<CopyrightInformation>© 2013 The Authors. International Journal of Clinical Practice Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lencioni</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Division of Diagnostic Imaging and Intervention, Pisa University Hospital and School of Medicine, Pisa, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kudo</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ye</LastName>
<ForeName>S-L</ForeName>
<Initials>SL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bronowicki</LastName>
<ForeName>J-P</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>X-P</ForeName>
<Initials>XP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dagher</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Furuse</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Geschwind</LastName>
<ForeName>J F</ForeName>
<Initials>JF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de Guevara</LastName>
<ForeName>L Ladrón</ForeName>
<Initials>LL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Papandreou</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takayama</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yoon</LastName>
<ForeName>S K</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nakajima</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lehr</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Heldner</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sanyal</LastName>
<ForeName>A J</ForeName>
<Initials>AJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>UL1 TR000058</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>11</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Int J Clin Pract</MedlineTA>
<NlmUniqueID>9712381</NlmUniqueID>
<ISSNLinking>1368-5031</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>25X51I8RD4</RegistryNumber>
<NameOfSubstance UI="D009536">Niacinamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9ZOQ3TZI87</RegistryNumber>
<NameOfSubstance UI="D000077157">Sorafenib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006528">Carcinoma, Hepatocellular</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009536">Niacinamide</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010671">Phenylurea Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077157">Sorafenib</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>11</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>11</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2016</Year>
<Month>4</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">24283303</ArticleId>
<ArticleId IdType="doi">10.1111/ijcp.12352</ArticleId>
<ArticleId IdType="pmc">PMC4265239</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Hepatology. 2011 Mar;53(3):1020-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21374666</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Clin Pract. 2012 Jul;66(7):675-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22698419</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1106-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20300004</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Gastroenterol Hepatol. 2006 Mar;4(3):369-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16527702</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Best Pract Res Clin Gastroenterol. 2007;21(1):161-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17223503</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Clin Pract. 2010 Jul;64(8):1034-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20642705</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2008 Jul 24;359(4):378-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18650514</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2004 Nov;127(5 Suppl 1):S179-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15508083</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2003 Dec 6;362(9399):1907-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14667750</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2009 Jan;10(1):25-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19095497</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2005 May 1;23(13):2892-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15860847</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hepatology. 2011 Dec;54(6):2055-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21898496</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Asian Pac J Cancer Prev. 2012;13(3):743-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22631642</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Liver Int. 2009 Apr;29(4):502-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19141028</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Radiother. 2011 Feb;15(1):3-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21239205</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2012 May;142(6):1264-1273.e1</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22537432</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2000 Dec 1;89(11):2266-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11147597</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>HPB (Oxford). 2005;7(1):35-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18333159</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hepatology. 2005 Nov;42(5):1208-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16250051</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>